NCT05006352 - A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 11, 2021

Primary Completion Date

December 15, 2022

Study Completion Date

June 5, 2024

Conditions

Amyotrophic Lateral Sclerosis

Interventions

DRUG

DNL343

Oral repeating dose

DRUG

Placebo

Oral repeating dose

Trial Locations (7)

Centre for Human Drug Research (CHDR), Leiden

Atrium Health Neurosciences Institute, Charlotte

Emory University, Atlanta

PPD Orlando, Orlando

HonorHealth, Scottsdale

University of California at San Diego, San Diego

California Pacific Medical Center, San Francisco